Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, TMTT, Surgical & IHFM | September 11, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date September 11, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,926 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Tax withholding · Disposed 398 · Balance 43,926 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 11, 2026 23:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 398 | $86.77 | $34,534.46 |
DisclosureSEC source: 0001225208-26-007775 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT, Surgical & IHFM 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,926 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). Read SEC document |
| August 26, 2026 Filed Aug 26, 2026 22:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 31,800 | $0.00 Strike: $72.68 | $0.00 |
DisclosureSEC source: 0001225208-26-007335 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT, Surgical & IHFM 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,800 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2026 Filed Aug 26, 2026 22:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 30,646 | $90.99 | $2,788,546.96 |
DisclosureSEC source: 0001225208-26-007335 · doc4.xml · nonDerivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT, Surgical & IHFM 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,324 F2 · price: This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 26, 2026 Filed Aug 26, 2026 22:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,154 | $91.76 | $105,892.66 |
DisclosureSEC source: 0001225208-26-007335 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT, Surgical & IHFM 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,970 F1 · price: This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 26, 2026 Filed Aug 26, 2026 22:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 31,800 | $72.68 | $2,311,224.00 |
DisclosureSEC source: 0001225208-26-007335 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT, Surgical & IHFM 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2026 Filed May 22, 2026 20:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,500 | $84.60 | $126,905.25 |
DisclosureSEC source: 0001225208-26-005576 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,324 F1 · price: This transaction was executed in multiple trades at prices ranging from $84.6002 to $84.6050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 13,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005170 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2 · derivative.expiration_date: These Performance Rights expire on May 10, 2030. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 7,538 | $79.96 | $602,738.48 |
DisclosureSEC source: 0001225208-26-005170 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,824 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005170 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,141 | $82.76 | $94,429.16 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · nonDerivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,779 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 9,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · derivative · entry 5 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,675 Underlying: Common Stock · 9,675 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,100 Underlying: Common Stock · 49,100 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 674 | $83.20 | $56,076.80 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,920 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 9,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,594 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2026 Filed May 4, 2026 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 282 | $83.98 | $23,682.36 |
DisclosureSEC source: 0001225208-26-004908 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,919 Read SEC document |
| December 11, 2025 Filed Dec 11, 2025 22:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,000 | $84.38 | $168,750.20 |
DisclosureSEC source: 0001225208-25-009873 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,201 Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 22:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-007991 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,201 F1 · shares: These restricted stock units were granted on September 11, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| August 25, 2025 Filed Aug 25, 2025 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $81.95 | $204,865.00 |
DisclosureSEC source: 0001225208-25-007460 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,996 F1 · price: This transaction was executed in multiple trades at prices ranging from $81.9401 to $81.9500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 22, 2025 Filed May 22, 2025 21:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,500 | $75.08 | $112,612.50 |
DisclosureSEC source: 0001225208-25-005388 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,496 Read SEC document |
| May 11, 2025 Filed May 12, 2025 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 580 | $73.68 | $42,734.40 |
DisclosureSEC source: 0001225208-25-004998 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,996 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004944 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 47,000 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004944 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004944 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,576 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 627 | $74.92 | $46,974.84 |
DisclosureSEC source: 0001225208-25-004944 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,376 Read SEC document |
| May 04, 2025 Filed May 5, 2025 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 289 | $75.65 | $21,862.85 |
DisclosureSEC source: 0001225208-25-004767 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,003 Read SEC document |
| May 03, 2025 Filed May 5, 2025 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 291 | $75.65 | $22,014.15 |
DisclosureSEC source: 0001225208-25-004767 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,292 Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 21:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,750 | $73.27 | $128,222.68 |
DisclosureSEC source: 0001225208-24-010631 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,583 Read SEC document |
| August 20, 2024 Filed Aug 20, 2024 23:42 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,250 | $69.95 | $87,437.63 |
DisclosureSEC source: 0001225208-24-008118 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,333 Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 821 | $86.72 | $71,197.12 |
DisclosureSEC source: 0001225208-24-005981 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,583 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005889 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 37,200 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005889 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,200 Underlying: Common Stock · 37,200 shares Expires 2031-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 447 | $85.09 | $38,035.23 |
DisclosureSEC source: 0001225208-24-005889 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,404 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005889 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,851 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 4,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005701 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,713 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 2,321 | $85.25 | $197,865.25 |
DisclosureSEC source: 0001225208-24-005701 · doc4.xml · nonDerivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,851 Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005701 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 03, 2024 Filed May 6, 2024 23:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 291 | $85.06 | $24,752.46 |
DisclosureSEC source: 0001225208-24-005701 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,459 Read SEC document |
| February 21, 2024 Filed Feb 21, 2024 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,000 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-24-002654 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2024 Filed Feb 21, 2024 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,000 | $86.75 | $607,267.50 |
DisclosureSEC source: 0001225208-24-002654 · doc4.xml · nonDerivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,750 F2 · price: This transaction was executed in multiple trades at prices ranging from $86.7455 to $86.7600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 21, 2024 Filed Feb 21, 2024 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,200 | $86.67 | $104,004.24 |
DisclosureSEC source: 0001225208-24-002654 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,750 F1 · price: This transaction was executed in multiple trades at prices ranging from $86.6600 to $86.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 21, 2024 Filed Feb 21, 2024 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,000 | $59.26 | $414,796.90 |
DisclosureSEC source: 0001225208-24-002654 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2023 Filed Dec 15, 2023 22:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,000 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-23-011152 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2023 Filed Dec 15, 2023 22:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,000 | $78.25 | $547,724.10 |
DisclosureSEC source: 0001225208-23-011152 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,950 F1 · price: This transaction was executed in multiple trades at prices ranging from $78.24 to $78.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2023 Filed Dec 15, 2023 22:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,000 | $59.26 | $414,796.90 |
DisclosureSEC source: 0001225208-23-011152 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2023 Filed Dec 6, 2023 22:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,500 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-23-010794 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 3,500 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2023 Filed Dec 6, 2023 22:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,500 | $70.00 | $245,005.60 |
DisclosureSEC source: 0001225208-23-010794 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,950 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 06, 2023 Filed Dec 6, 2023 22:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,500 | $59.26 | $207,398.45 |
DisclosureSEC source: 0001225208-23-010794 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. Read SEC document |
| October 03, 2023 Filed Oct 3, 2023 20:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 8,500 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-23-009259 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 8,500 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2023 Filed Oct 3, 2023 20:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,500 | $70.00 | $595,000.00 |
DisclosureSEC source: 0001225208-23-009259 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,950 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. Read SEC document |
| October 03, 2023 Filed Oct 3, 2023 20:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,500 | $59.26 | $503,681.95 |
DisclosureSEC source: 0001225208-23-009259 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.